Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ FCEL Investors Have Opportunity to Lead FuelCell Energy, Inc. Securities Fraud Lawsuit (PR Newswire) +++ FUELCELL Aktie +3,46%

News zum Sektor Gesundheit aus Finnland

Zum Sektor Gesundheit gehören Unternehmen der Pharmaka- & Biotechnologiebranche, Produzenten von medizintechnischen Geräten, Gesundheitsdienste, Kliniken und Pflegeeinrichtungen.
 >Gesundheit ETFs & Fonds 
Es sind 101 ETFs & Fonds zum Sektor Gesundheit bekannt.
 >Aktien zum Sektor Gesundheit 
Es sind 1530 Aktien zum Sektor Gesundheit bekannt.
 
12.10.26 - 17:01
Composition of Bioretec′s Shareholders′ Nomination Board (Cision)
 
Bioretec Ltd, Company release, 12 October 2026 at 6:00 p.m. EEST The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Tor-Oskar Karlberg from Stephen Industries Inc Oy, Rami Vehmas from Keskinäinen Eläkevakuutusyhtiö Ilmarinen and Johan Hamström from Sp-Rahastoyhtiö Oy. The Nomination Board has elected Tor-Oskar Karlberg as its chairperson at its organizational meeting on 12 October, 2026. The chairperson of the Board of Directors of Bioretec acts as an expert to the Nomination Board without voting right. In accordance with the Charter of the...
09.10.26 - 14:24
Faron Pharmaceuticals keeps Stifel backing ahead of BEXERA test (Proactive Investors)
 
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...
08.10.26 - 15:00
Inside information: Bioretec initiates change negotiations to improve operational efficiency and competitiveness (Cision)
 
Bioretec Ltd, Inside Information, 8 October 2026 at 4:00 p.m. EEST Bioretec Ltd will initiate change negotiations in accordance with the Co-operation Act as part of the development of the company's organization and operating model. The objective of the negotiations is to strengthen the company's performance, improve operational efficiency, and enhance Bioretec's competitiveness and long-term growth prospects. The change negotiations are part of a broader organizational and operating model transformation aimed at creating a clearer, more efficient organization that better supports the...
08.10.26 - 08:30
Faron Pharmaceuticals Ltd: Reminder for Investors, Analysts and Media to Register for Upcoming R&D Day (Accesswire)
 
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Faron's R&D Day takes place on 8 October 2026 TURKU, FI / ACCESS Newswire / October 8, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a globa......
07.10.26 - 13:01
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings (Cision)
 
Optomed Plc Stock Exchange Release 7 October 2026 at 14.00, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Sp-Rahastoyhtiö Oy (“Notifier”). According to the notification, the aggregate holding of the investment funds managed by Sp-Rahastoyhtiö Oy, Säästöpankki Pienyhtiöt and Säästöpankki Kotimaa, in Optomed's shares and voting rights amounted to 4.91...
07.10.26 - 08:01
125,000 Orion Corporation A shares converted into B shares (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST        ...
06.10.26 - 09:18
Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe (AFX)
 
HELSINKI (dpa-AFX) - Orion Corp. (0M2N.L, ORNAV.HE, ORNBV.HE) and Qilu Pharma Europe have entered into an agreement to commercialise an intravenous (IV) pembrolizumab biosimilar in Europe.Pembroli......
06.10.26 - 08:30
Faron Pharmaceuticals: Composition of Faron Pharmaceutical′s Shareholders′ Nomination Board (Accesswire)
 
TURKU, FI / ACCESS Newswire / October 6, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments......
06.10.26 - 08:01
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market (GlobeNewswire EN)
 
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST        ...
05.10.26 - 14:01
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company′s first biologic candidate to reach clinical testing (GlobeNewswire EN)
 
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing....
01.10.26 - 08:30
Faron Pharmaceuticals: Faron Announces First Patient Dosed in BLAZE Investigator-Initiated Trial (Accesswire)
 
First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumors TURKU, FI / ACCESS Newswire / October 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE......
30.09.26 - 08:30
Faron Pharmaceuticals Ltd: Convertible Bond Amortization Payment Deferred by Mutual Agreement With HCM (Accesswire)
 
TURKU, FI / ACCESS Newswire / September 30, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Compa......
30.09.26 - 08:06
Orion Corporation completed share acquisitions (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE30 SEPTEMBER 2026 at 9.05 EEST        ...
30.09.26 - 08:01
Orion Corporation: Acquisition of own shares during week 40, 2026 (GlobeNewswire EN)
 
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY'S OWN SHARES30/09/2026 at 09.00 EEST        ...
28.09.26 - 15:36
Optomed Oyj - Managers′ Transactions - Piila (Cision)
 
Optomed Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Laura Piila Position: Other senior manager  Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 174346/4/4   ____________________________________________ Transaction date: 2026-09-25 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: Optomed Oyj:n optio-oikeus 2025A Nature of transaction:...
28.09.26 - 15:30
Optomed Oyj - Managers′ Transactions - Myllylä (Cision)
 
Optomed Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Markku Myllylä Position: Other senior manager  Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 174354/4/4   ____________________________________________ Transaction date: 2026-09-25 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: Optomed Oyj:n optio-oikeus 2025A Nature of transaction:...
28.09.26 - 15:24
Optomed Oyj - Managers′ Transactions - Knuutti (Cision)
 
Optomed Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Sakari Knuutti Position: Other senior manager  Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 174361/4/4   ____________________________________________ Transaction date: 2026-09-25 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: Optomed Oyj:n optio-oikeus 2025A Nature of transaction:...
28.09.26 - 15:18
Optomed Oyj - Managers′ Transactions - Himberg (Cision)
 
Optomed Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Juho Himberg Position: Chief Executive Officer  Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 174339/4/4   ____________________________________________ Transaction date: 2026-09-25 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: Optomed Oyj:n optio-oikeus 2025A Nature of...
25.09.26 - 18:02
Orion Corporation: Acquisition of own shares during week 39, 2026 (GlobeNewswire EN)
 
Orion Corporation: Acquisition of own shares during week 39, 2026...
25.09.26 - 14:36
Optomed′s Board of Directors has resolved to establish a new stock option plan (Cision)
 
Optomed Plc Stock Exchange Release 25 September 2026 at 15.30, Helsinki Optomed's Board of Directors has resolved to establish a new stock option plan Optomed's Board of Directors has resolved upon a new option plan. The resolution is based on the authorization granted by the General Meeting of 8 May 2026.   Option plan 2026A: The total number of options is 613 130 and each option entitles to one share of the Company. The options are offered to the CEO and certain key employees. The purpose of the plan is to retain and incentivize the CEO and other key employees. The share...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Quod non vetat lex, hoc vetat fieri pudor - Was kein Gesetz verbietet, verbietet doch der Anstand. - Seneca
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!